US Stock MarketDetailed Quotes
ONCY Oncolytics Biotech
- 1.180
- -0.010-0.84%
Close May 8 16:00 ET
- 1.170
- -0.010-0.85%
Post 18:31 ET
89.00MMarket Cap-3946P/E (TTM)
1.190High1.151Low92.26KVolume1.170Open1.190Pre Close108.17KTurnover0.14%Turnover RatioLossP/E (Static)75.42MShares3.39452wk High4.44P/B80.68MFloat Cap0.88352wk Low--Dividend TTM68.37MShs Float7.400Historical High--Div YieldTTM3.28%Amplitude0.351Historical Low1.172Avg Price1Lot Size
Oncolytics Biotech Stock Forum
Sign in to post a comment
$Oncolytics Biotech(ONCY.US$ You were supposed to drop after my post! Not go up a bit! Grrrr! Hehehe
2
5
$Oncolytics Biotech(ONCY.US$ Ifn you drop to a 1.00? Ima start scaling in for a swing, in preparation for a answer from the FDA for your next phase trial design! NFA Just thinking outloud! Hehehe![]()
$Oncolytics Biotech(ONCY.US$ Oncolytics Biotech Reports Submission Of A Type C Meeting Request To FDA
Benzinga· 3 mins ago
This meeting aims to discuss the company's planned registration-enabling trial for pelareorep in HR+/HER2- metastatic breast cancer (mBC). "We hope to meet with the agency in Q2 2024 and look forward to a productive dialogue. With anticipated overall survival data from the BRACELET-1 study and productive discussions with the FDA, 2024 is poised to be a tr...
Benzinga· 3 mins ago
This meeting aims to discuss the company's planned registration-enabling trial for pelareorep in HR+/HER2- metastatic breast cancer (mBC). "We hope to meet with the agency in Q2 2024 and look forward to a productive dialogue. With anticipated overall survival data from the BRACELET-1 study and productive discussions with the FDA, 2024 is poised to be a tr...
$Oncolytics Biotech(ONCY.US$
NEWS
Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA
Oncolytics Biotech Inc. announces a Type C meeting request with the FDA for a registration-enabling trial in HR+/HER2- metastatic breast cancer. Positive results from the BRACELET-1 trial and upcoming overall survival data in H2 2024 indicate a transformative year ahead.
NEWS
Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA
Oncolytics Biotech Inc. announces a Type C meeting request with the FDA for a registration-enabling trial in HR+/HER2- metastatic breast cancer. Positive results from the BRACELET-1 trial and upcoming overall survival data in H2 2024 indicate a transformative year ahead.
1
Patricia S. Andrews joining Oncolytics Biotech Inc.'s Board of Directors is viewed positively. Her vast experience in oncology and business development is anticipated to offer valuable insights and strategic direction as the company gears up for crucial studies with pelareorep in breast and pancreatic cancers.
$Oncolytics Biotech(ONCY.US$ Oncolytics Biotech Brief: Cash Position Stands at $40.0 Million With a Projected Cash Runway Through Critical Milestones, Including BRACELET-1 Survival Data! Important meaning they think news of meeting milestones coming soon? At least soon enough that they dont need the cash right now? WATCHING CLOSELY ![]()
$Oncolytics Biotech(ONCY.US$ Oncolytics Biotech Brief: Adds Presented "Positive" Updated Pancreatic Cancer Data From GOBLET Phase 1/2 Study At ESMO
MT Newswires· 2 mins ago![]()
MT Newswires· 2 mins ago
$Oncolytics Biotech(ONCY.US$ Oncolytics Biotech Bags $5M Therapeutic Accelerator Award From The Pancreatic Action Network
1
$Oncolytics Biotech(ONCY.US$
Free motley fool today
These Canadian Biotech’s are Quietly Changing the Face of Healthcare.
https://ca.finance.yahoo.com/news/canadian-biotech-stocks-quietly-changing-130000657.html
Free motley fool today
These Canadian Biotech’s are Quietly Changing the Face of Healthcare.
https://ca.finance.yahoo.com/news/canadian-biotech-stocks-quietly-changing-130000657.html
$Oncolytics Biotech(ONCY.US$
Pancreatic cancer Anouncement P3 with Checkpoint inhibitor coming in less than 90 days
PANCAN is sponsoring trial very innovative clinical trial. 50% saving in clinical trial costs.
now. Very Promising. No treatments for Pancreatic cancer.
possible P3 in Breast as well
Colorectal data in October at Spain ESMO.
lots of catalysts coming
Pancreatic cancer Anouncement P3 with Checkpoint inhibitor coming in less than 90 days
PANCAN is sponsoring trial very innovative clinical trial. 50% saving in clinical trial costs.
now. Very Promising. No treatments for Pancreatic cancer.
possible P3 in Breast as well
Colorectal data in October at Spain ESMO.
lots of catalysts coming
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
MonkeyGee : GL drop 50%
TrytosaveabitOP MonkeyGee: Yeah if you’re talking about that drop starting back in July? It was the start of a lot being pissed at the offering at a discount! Hehehe! But you see, im not afeared! Hehehe. I look at it as a good place to start a swing! Because I believe in 6+ weeks or so! The FDA will approve the go forward and I will grab a quick 50%+! Hehehe!
MonkeyGee TrytosaveabitOP: No, globe life (GL) dropped 50% today
TrytosaveabitOP MonkeyGee: Oh! Hehehe! I thought you was saying ( GL= Good Luck ) with that! It’s dropped 50%! LMAO!
Newbee4 TrytosaveabitOP: lol